Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 17;3(3):392–405. doi: 10.1002/hep4.1303

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

IL‐22BP inhibits hepatocellular IL‐22 signaling. (A) Expression of IL‐22Rα on Huh‐7 and HepG2 cells. IL‐22Rα was labeled with AF488 and nuclei were stained with DAPI (4´,6‐diamidino‐2‐phenylindole). (B) IL‐22 induces Stat1 and Stat3 phosphorylation in Huh‐7 and HepG2 cells. (C) IL‐22BP inhibits IL‐22‐induced Stat1 and Stat3 phosphorylation at physiological dose ranges. (D) IL‐22BP inhibits IL‐22 downstream signaling in primary human hepatocytes. Primary human hepatocytes were stimulated with or without 5 ng/mL of IL‐22 and ascending concentrations of IL‐22BP for 15 minutes, as indicated, and cellular phospho‐Stat3, total Stat3, and β‐actin protein levels were quantified by immunoblot analysis.